The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma
ABSTRACT The increase of incidences of Hepatocellular Carcinoma (HCC) will continue in the next decades. The therapies about hepatitis C infection has been questioned as a risk factor. Some authors emphasized that sustained virologic response (SVR) with interferon- based therapy reduced the risk of developing HCC. In contrast, some publications that to suggest an increasing risk of HCC in patients treated with Direct-Acting Antivirals (DAA). Whether these therapies are associated with an increased risk of HCC remains to be studied and continued long-term observational studies will be needed. The goal in HCV care needs to go beyond merely achieving an SVR.
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Asociación Mexicana de Hepatología A.C.
2017
|
| Online Access: | http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1665-26812017000300328 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|